Skip to main content
SpringerLink
Log in

Die Frühinstillation des Harnblasenkarzinoms

Eine Standortbestimmung

Single early postoperative instillation in superficial bladder carcinoma—current status

  • Übersichten
  • Published:
Der Urologe, Ausgabe A Aims and scope Submit manuscript

Zusammenfassung

Die hohen Rezidivraten beim oberflächlichen Harnblasenkarzinom (>70%) sind multifaktoriell bedingt. Durch Tumorzellverschleppung während des transurethralen Eingriffs, inkomplette Resektionen und übersehene oder neu entstandene Tumoren müssen engmaschige Nachsorgen und wiederholte Operationen erfolgen. Die Frühinstillation beeinflusst das Auftreten der Rezidive positiv und wurde daher in die Europäischen Leitlinien 2001 integriert. Menge, Konzentration, Substanz und Applikationsdauer sind bisher nicht standardisiert worden. In einer Analyse der publizierten Literatur finden sich viele unterschiedliche Formen der Frühinstillation im Hinblick auf Substanzen, Konzentrationen, Instillationsdauer und Applikationszeitpunkt, sodass ein direkter Vergleich schwierig ist und eine richtungweisende Standardisierung durch weitere Studien erfolgen muss.

Abstract

The high recurrence rate in superficial bladder cancer (>70%) is caused by the adhesion of free floating tumor cells during transurethral treatment, by incomplete resections, and by overlooked and new tumors. Frequent follow-ups and reoperations are necessary. A single immediate instillation after TUR shows positive effects in reducing recurrence rates and is therefore recommended in the European Guidelines from 2001. The amount, concentration, instillation time, and substances have not yet been standardized. By analyzing the literature we found many different techniques of early instillation therapy. Different substances, concentrations, varying instillation times, and application times make a comparison of these studies very difficult. Further studies are needed to standardize early postoperative instillation therapy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Literatur

  1. Au JL, Badalament RA, Wientjes MG, Young DC et al. (2001) Methods to improve efficacy of intravesical mitomycin C: results of a randomized phase III trial. J Natl Cancer Inst 93 (8): 597–604

    Article  CAS  PubMed  Google Scholar 

  2. Beisland HO, Seland P (1986) A prospective randomized study on neodym-yag laser Irridation versus TUR in the treatment of urinary bladder cancer. Scand J Urol Nephrol 20: 209–212

    CAS  PubMed  Google Scholar 

  3. Bouffioux C, Kurth KH, Bono A et al. (1995) Intravesical adjuvant chemotherapy for superficial transitional cell bladder carcinoma: results of 2 European Organization for Research and Treatment of Cancer randomized trials with mitomycin C and doxorubicin comparing early versus delayed instillations and short-term versus long-term treatment. European Organization for Research and Treatment of Cancer Genitourinary Group. J Urol Mar 153 (3 Pt 2): 934–941

    CAS  Google Scholar 

  4. Burnand KG, Boyd PJ, Mayo ME et al. (1976) Single dose intravesical thiotepa as an adjuvant to cystodiathermy in the treatment of transitional call bladder carcinoma. BJU 48: 55–59

    CAS  PubMed  Google Scholar 

  5. Calais da Silva F, Denis L, Bono A, Bollack C, Bouffioux C (1988) Intravesical chemoresection with 4’-epi-doxorubicin in patients with superficial bladder tumors. Eur Urol 14 (3): 207–209

    PubMed  Google Scholar 

  6. Filbeck T, Pichlmeier U, Knuechel R, Wieland WF, Rossler W (2003) Reducing the risk of superficial bladder cancer recurrence with 5-aminolevulinic acid-induced fluorescence diagnosis. Results of a 5-year study. Urologe A 42 (10): 1366–1373

    Article  CAS  PubMed  Google Scholar 

  7. Kaasinen E, Rintala E, Hellström P et al. (2002) Factors explaining recurrence in patients undergoing chemoimmunotherapy regimens for frequently recurring superficial bladder carcinoma. Europ Urol 42: 167–174

    Article  Google Scholar 

  8. Mack D, Rammal E, Jakse G (1988) Iatrogenic Tumorzellimplantation beim Blasenkarzinom. Urologe A 27: 99–104

    CAS  PubMed  Google Scholar 

  9. Müller F, Kraft R, Zingg EJ (1985) Exfoliative cytology after transurethral resection of superficial bladder tumours. Br J Urol 57: 530

    PubMed  Google Scholar 

  10. Newling DW, Hetherington J, Sundaram SK, Robinson MR, Kisbenedek L (2001) The use of valrubicin for the chemoresection of superficial bladder cancer—a maker lesion study. Eur Urol 39(6): 643–647

    Article  CAS  PubMed  Google Scholar 

  11. Oosterlinck W, Lobel B, Jakse G, Malmström P-U, Stöckle M, Sternberg C (eds) (2001) Guidelines on bladder cancer. European Association of Urology. http://www.uroweb.org, pp 8–11

  12. Pode D, Alon Y, Horowitz AT, Vlodavsky I, Biran S (1986) The mechanism of human bladder tumor implantation in an in vitro model. J Urol 136(2): 482–486

    CAS  PubMed  Google Scholar 

  13. Popert RJ, Goodall J, Coptcoat MJ, Thompson PM, Parmar MK, Masters JR (1994) Superficial bladder cancer: the response of a marker tumour to a single intravesical instillation of epirubicin. Br J Urol 74 (2): 195–199

    CAS  PubMed  Google Scholar 

  14. Rajala P, Liukkonen T, Raitanen M et al. (1999) Transurethral resection with perioperative instilation on interferon-alpha or epirubicin for the prophylaxis of recurrent primary superficial bladder cancer: a prospective randomized multicenter study—Finnbladder III. J Urol 161 (4): 1133–1135

    Article  CAS  PubMed  Google Scholar 

  15. Rajala P, Kaasinen E, Raitanen M, Liukkonen T, Rintala E, Finnbladder Group (2002) Perioperative single dose instillation of epirubicin or interferon-alpha after transurethral resection for the prophylaxis of primary superficial bladder cancer recurrence: a prospective randomized multicenter study—Finnbladder III long-term results. J Urol 168 (3): 981–985

    Article  CAS  PubMed  Google Scholar 

  16. Semple JE (1948) Papillomata of bladder treated with podophyllin. Br Med J 26: 1235–1237

    Google Scholar 

  17. Soloway MS, Masters S (1980) Urothelial susceptibility to tumor cell implantation: influence of cauterisation. Cancer 46: 1158

    CAS  PubMed  Google Scholar 

  18. Sylvester RJ, Oosterlinck W, van der Meijden AP (2004) A single immediate postoperative instillation of chemotherapy decreases the risk of recurrence in patients with stage Ta T1 bladder cancer: a meta-analysis of published results of randomized clinical trials. J Urol 171: 2186–2190

    Article  PubMed  Google Scholar 

Download references

Interessenkonflikt:

Keine Angaben

Author information

Authors and Affiliations

  1. Urologische Universitätsklinik Mannheim

    S. Langbein, A. Häcker, J. K. Badawi, M. S. Michel & P. Alken

  2. Urologische Universitätsklinik, Theodor-Kutzer-Ufer 1–3, 68167, Mannheim

    S. Langbein

Authors
  1. S. Langbein
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. A. Häcker
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. J. K. Badawi
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. M. S. Michel
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. P. Alken
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to S. Langbein.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Langbein, S., Häcker, A., Badawi, J.K. et al. Die Frühinstillation des Harnblasenkarzinoms. Urologe [A] 43, 1531–1536 (2004). https://doi.org/10.1007/s00120-004-0720-5

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00120-004-0720-5

Schlüsselwörter

Keywords

Search

Navigation